10-Q: Medinotec Inc. Reports Increased Revenue but Net Loss Widens in Q3 2023

Medinotec Inc. saw a significant increase in revenue for the quarter ended November 30, 2023, driven by new distribution agreements and U.S. sales of its Trachealator product, but the company's net loss also widened during the period.

Summary

• Medinotec Inc. reported revenue of $2,002,547 for the quarter ended November 30, 2023, compared to $387,989 for the same period in the prior year.
• Revenue for the nine months ended November 30, 2023, was $2,769,547, up from $720,339 in the prior year.
• The increase in revenue is attributed to new distribution agreements in South Africa and sales of the Trachealator in the United States.
• The company's cost of goods sold increased to $1,138,628 for the quarter and $1,298,116 for the nine months, reflecting the higher sales volume.
• Operating expenses also increased to $606,009 for the quarter and $1,116,936 for the nine months, driven by general and administrative expenses and compliance costs.
• The company's net loss widened to $429,371 for the quarter and $503,248 for the nine months, compared to losses of $36,341 and $289,077 in the prior year periods.
• As of November 30, 2023, the company had total current assets of $3,594,093 and working capital of $3,257,903.
• The company fully reserved for a $629,458 note receivable from Innovative Outcomes due to a strategic shift.
• The company identified material weaknesses in its internal control over financial reporting.
• The company leases office and warehouse space under noncancelable operating lease agreements, which became effective on August 1, 2023, for a period of 3 years, terminating July 31, 2026.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While revenue increased significantly, the net loss also widened, and material weaknesses in internal control were identified. The company has positive prospects with the Trachealator and new distribution agreements, but faces challenges in profitability and internal controls.

Positives

• Significant revenue growth driven by new distribution agreements and U.S. sales of the Trachealator.
• The company has enough cash reserves and working capital to fund the roll out in the market of the United States including new research and development activities and Marketing and Sales functions.
• The company obtained a significant distribution revenue stream in South Africa.
• Operating activities provided cash of $101,232 for the nine months ending November 30, 2023, whereas operating activities used cash $848,140 for the nine months ending November 30, 2022.

Negatives

• Net loss widened to $429,371 for the quarter and $503,248 for the nine months.
• The company fully reserved for a $629,458 note receivable from Innovative Outcomes due to a strategic shift.
• The company identified material weaknesses in its internal control over financial reporting.
• The company's disclosure controls and procedures were not effective at the reasonable assurance level due to the material weaknesses identified.

Risks

• The company relies on distributors for the sale of its products abroad and are entering into new agreements for the United States.
• The company relies on a limited number of subcontractors to manufacture, assemble, package and production test our products, and the failure of any of these third-party subcontractors to deliver products or otherwise perform as requested could damage our relationships with our customers, decrease our sales and limit our growth.
• The company distributes commodity medical products on behalf of multinational firms for a substantial portion of our sales, and our failure to maintain and further develop these relationships could harm our business.
• The company may not be able to successfully implement our growth strategy for our own branded products as a result of the distribution efforts we engage in of outside product offerings we distribute for.

Future Outlook

The company expects to see an increase in sales and marketing expenses to build out the territory of the United States and expects the distribution products to add to the product basket of the business and ensure more revenues are generated in the Company.

Management Comments

• Management believes the company is a global leader in tracheal non-occlusive airway dilation technology.
• Management found it prudent to plan a roll out of the product with a distributor that had an established network and infrastructure.

Industry Context

The company operates in the medical device industry, specifically in the areas of cardiovascular and upper airway healthcare. The report mentions the increasing prevalence of tracheal stenosis due to extended tracheal intubation in a post-COVID-19 world, highlighting a growing market need for the company's Trachealator product.

Comparison to Industry Standards

• The company's Trachealator is described as a world first in its ability to dilate a patient's airway while maintaining ventilation, suggesting a competitive advantage over occlusive airway dilation balloons.
• The company's Cape Cross PTCA Catheter competes with other interventional balloons in the market.
• The OUTFLO Aortic Perfusion and Dilation Catheter is being developed for the rapidly growing Transcatheter Aortic Valve Implantation (TAVI) market.

Related Party Transactions

• DISA Medinotec leases commercial buildings from Minoan Capital Proprietary Limited (Minoan Capital).
• Rent expense paid to Minoan Capital was $7,797 for the quarter ending November 30, 2023.

Stakeholder Impact

• Shareholders: The increased revenue is a positive sign, but the widening net loss and identified material weaknesses in internal control are concerning.
• Employees: The company plans to hire additional employees to address the segregation of duties issue, which could improve the work environment.
• Customers: The company's focus on developing innovative medical devices could lead to improved treatment options for patients.
• Suppliers: The company's increased sales could lead to increased demand for suppliers' products and services.

Next Steps

• The company intends to remedy its material weaknesses with regard to insufficient segregation of duties by hiring additional employees in order to segregate duties in a manner that establishes effective internal controls once resources become available.
• The company expects to see an increase in sales and marketing expenses to build out the territory of the United States.

Key Dates

Keywords

Medinotec, Trachealator, revenue, net loss, distribution agreements, medical devices, financial results, internal control, South Africa, United States